Our experts supported a pharmaceutical company in providing evidence regarding the cost-effectiveness and budgetary impact of antidepressants to document the reimbursement decision.
About the Client
A large innovative pharmaceutical company presents globally.
To document the reimbursement decision, the company needed to show rigorous evidence regarding the drug’s cost-efficacy and budgetary impact.
Business Consulting Solution
The severity of depression was measured with the Montgomery Asberg Depression Rating Scale (MADRS) and quality-adjusted life-years scale (QALY). The costs included all the direct and indirect costs per patient associated with the two procedures. The economic evaluation was conducted from a societal perspective, including costs related to intervention, unpaid work, informal care, and absenteeism from paid work. The ICER, CE plane, CE acceptability curve documented the analysis.
The research findings allowed the healthcare provider to prove that their drugs were cost-effective when compared to standard care and get approval for reimbursement.